System for targeted delivery of therapeutic agents

• US 8,709,483 B2
• Filed: 09/26/2008
• Issued: 04/29/2014
• Est. Priority Date: 03/31/2006
• Status: Active Grant

• Current Assignee: Brigham and Women's Hospital Incorporated, Massachusetts Institute of Technology
• Original Assignee: Brigham and Women's Hospital Incorporated, Massachusetts Institute of Technology
• Inventors: Farokhzad, Omid C., Cheng, Jianjun, Teply, Benjamin A., Langer, Robert S., Zale, Stephen E.
• Primary Examiner(s): Popa, Ileana
• Application Number:
  US12/239,136
• Publication Number:
  US 20100266491A1
• Time in Patent Office: 2,041 Days
• Field of Search: None
• US Class Current: 424/489
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 47/549 Sugars, nucleosides, nucleotides or nucleic acids
• CPC Class Codes: A61K 47/555 pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
• CPC Class Codes: A61K 47/593 Polyesters, e.g. PLGA or polylactide-co-glycolide
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61K 47/6937 the polymer being PLGA, PLA or polyglycolic acid
• CPC Class Codes: A61K 51/0417 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 51/0491 Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
• CPC Class Codes: A61K 51/0495 Pretargeting
• CPC Class Codes: A61K 51/065 conjugates with carriers being macromolecules
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5153 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5192 Processes
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.

Claims

1. A targeted particle comprising polymer conjugated to a surfactant, hydrophilic polymer or lipid,

the particle having bound thereto a plurality of small molecule targeting moieties that specifically bind to the Zn2+ NAAG/PSMA binding pocket within prostate specific membrane antigen (PSMA) selected from the group consisting of 2-PMPA, GPI5232, VA-033 2MPPA, thiol and indole thiol based PSMA inhibitors, 3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid derivative PSMA inhibitors, hydroxamate derivative PSMA inhibitors, PDBA-based PSMA inhibitors, and urea-based PSMA inhibitors, and

having encapsulated or dispersed therein a therapeutic, diagnostic or prophylactic agent,

wherein at least 80% of the particles have a greatest dimension less than 250 nm and have enhanced permeation through tumor vasculature and retention in tumor tissue as compared to particles greater than 250 nm.

2. The targeted particle of claim 1, wherein the polymer is selected from the group consisting of poly(lactide-co-glycolide) (PLGA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), polycaprolactone, and polyanhydrides.

3. The targeted particle of claim 1, wherein the polymer is PLA.

4. The targeted particle of claim 1, wherein the particle comprises two or more polymers.

5. The targeted particle of claim 4, wherein at least one polymer is selected from the group consisting of polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, and combinations thereof.

6. The targeted particle of claim 4, wherein at least one polymer is selected from the group consisting of polyesters, polyanhydrides, polyethers, polyurethanes, polymethacrylates, polyacrylates, and polycyanoacrylates.

7. The targeted particle of claim 4, wherein at least one polymer is polyalkylene glycol.

8. The targeted particle of claim 4, wherein at least one polymer is polyethylene glycol (PEG).

9. The targeted particle of claim 1, wherein the conjugated polymer comprises a copolymer of two or more polymers.

10. The targeted particle of claim 9, wherein the conjugated copolymer is a copolymer of PLA and PEG.

11. The targeted particle of claim 1, wherein the targeted particle comprises a protein, lipid, or carbohydrate.

12. The targeted particle of claim 1, wherein the small molecule targeting moiety is selected from the group consisting of urea-based inhibitors.

13. The targeted particle of claim 1, wherein the therapeutic agent is selected from the group consisting of small molecules, proteins, nucleic acids, carbohydrates, lipids, and combinations thereof.

14. The targeted particle of claim 1, wherein the therapeutic agent is an anti-cancer agent.

15. The targeted particle of claim 1, wherein the therapeutic agent is selected from the group consisting of antibodies, recombinant antibodies, humanized antibodies, characteristic portions thereof, and combinations thereof.

16. The targeted particle of claim 1, wherein the therapeutic agent is an enzyme.

17. The targeted particle of claim 1, wherein the therapeutic agent is a small interfering RNA, a small hairpin RNA, or a microRNA.

18. The targeted particle of claim 1, wherein at least 90% of the particles have a greatest dimension less than 200 nm in diameter.

19. The targeted particle of claim 1, wherein the prophylactic agent is a vaccine.

20. The targeted particle of claim 1, wherein the therapeutic agent is docetaxel.

21. The targeted particle of claim 1, wherein the targeting moiety is associated with the particle via at least one covalent linkage.

34. The targeted particle of claim 1, wherein the conjugated polymer is a copolymer of PLA and PEG, and wherein the therapeutic agent is docetaxel.

35. The targeted particle of claim 34, wherein the greatest dimension of the particles is between 25 nm and 200 nm in diameter.

36. The targeted particle of claim 1, wherein the therapeutic agent is a taxane.

37. The targeted particle of claim 1, wherein the targeting moiety increases intratumor levels of the therapeutic agent by at least three-fold.

39. The targeted particle of claim 1, wherein at least 80% of the particles have a greatest dimension less than 200 nm.

40. The targeted particle of claim 1, wherein at least 90% of the particles have a greatest dimension less than 200 nm.

43. The targeted particle of claim 1 having bound thereto a plurality of small molecule targeting moieties that specifically bind to the Zn2+ NAAG/PSMA binding pocket within prostate specific membrane antigen (PSMA) selected from the group consisting of 2-PMPA, GPI5232, VA-033, and 2-MPPA.

22. A method of treating prostate cancer in a subject, comprising administering an effective amount to a subject in need thereof of particles comprising polymer conjugated to a surfactant, hydrophilic polymer or lipid,

the particle having bound thereto a plurality of small molecule targeting moieties that specifically bind to the Zn2+ NAAG/PSMA binding pocket within prostate specific membrane antigen (PSMA) selected from the group consisting of 2-PMPA, GPI5232, VA-033, thiol and indole thiol based PSMA inhibitors, 3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid derivative PSMA inhibitors, hydroxamate derivative PSMA inhibitors, PDBA-based PSMA inhibitors, and urea-based PSMA inhibitors,

having encapsulated or dispersed therein a therapeutic, diagnostic or prophylactic agent,

wherein at least 80% of the particles have a greatest dimension less than 250 nm and have enhanced permeation through tumor vasculature and retention in tumor tissue as compared to particles greater than 250 nm.

23. The method of claim 22, wherein the targeted particle further comprises a pharmaceutically acceptable excipient.

24. The method of claim 22, wherein the targeted particle is administered to the subject by an intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, or intraventricular, route.

25. The method of claim 22, wherein the targeted particle is administered directly to the prostate.

26. The method of claim 22, wherein the targeted particle is administered directly to prostate cancer cells.

27. The method of claim 26, wherein the targeted particle is administered directly to prostate cancer cells by topical administration.

28. The method of claim 26, wherein the targeted particle is administered directly to prostate cancer cells by injection into tissue comprising the prostate cancer cells.

29. The method of claim 26, wherein the targeted particle is administered to the subject by implantation of targeted particles at or near prostate cancer cells by stereotactic surgery.

30. The method of claim 26, wherein the targeted particle is administered to the subject by implantation of targeted particles at or near prostate cancer cells during surgical removal of a tumor.

31. A method of preparing particles comprising polymer conjugated to a surfactant, hydrophilic polymer or lipid,

the particle having bound thereto a plurality of protein or small molecule targeting moieties that specifically bind to the particle having bound thereto a plurality of small molecule targeting moieties that specifically bind to the Zn2+ NAAG/PSMA binding pocket within prostate specific membrane antigen (PSMA) selected from the group consisting of 2-PMPA, GPI5232, VA-033, thiol and indole thiol based PSMA inhibitors, 3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid derivative PSMA inhibitors, hydroxamate derivative PSMA inhibitors, PDBA-based PSMA inhibitors, and urea-based PSMA inhibitors, and

having encapsulated or dispersed therein a therapeutic, diagnostic or prophylactic agent,

wherein at least 80% of the particles have a greatest dimension less than 250 nm and have enhanced permeation through tumor vasculature and retention in tumor tissue as compared to particles greater than 250 nm, comprising nanoprecipitation or flow focusing fluidic channels of polymer conjugated to a surfactant, hydrophilic polymer or lipid, in combination with a therapeutic, diagnostic or prophylactic agent and targeting moieties that specifically binding to prostate specific membrane antigen selected from the group consisting of 2-PMPA, GPI5232, VA-033, thiol and indole thiol based PSMA inhibitors, 3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid derivative PSMA inhibitors, hydroxamate derivative PSMA inhibitors, PDBA-based PSMA inhibitors, and urea-based PSMA inhibitors, and selecting the particles having a greatest dimension less than 250 nm.

32. A population of targeted particles, comprising

a particle comprising a polymeric matrix, wherein the polymeric matrix comprises a polyester;

a targeting moiety wherein the targeting moiety is a urea-based prostate specific membrane antigen (PSMA) inhibitor; and

a therapeutic agent;

wherein at least 80% of the particles have a greatest dimension less than 250 nm,

having encapsulated or dispersed therein a therapeutic, diagnostic or prophylactic agent, and

having enhanced permeation through tumor vasculature and retention in tumor tissue as compared to particles greater than 250 nm.

33. The targeted particle of claim 32, wherein the urea-based inhibitor is selected from the group consisting of ZJ 43, ZJ 11, ZJ 17, and ZJ 38.

38. The targeted particle of claim 32, wherein at least 90% of the particles have a greatest dimension less than 250 nm.

41. The targeted particle of claim 32, wherein at least 80% of the particles have a greatest dimension less than 200 mm.

42. The targeted particle of claim 32, wherein at least 90% of the particles have a greatest dimension less than 200 nm.